企業プロフィール
Gilead Sciences 株価・ニュース・カタリスト
- ティッカー:
- GILD
- 取引所:
- NASDAQ
- セクター:
- Infectious Disease, Biopharma, Nucleic Acid Drugs, CAR-T Therapy, Gene Therapy
- 所在地:
- United States
株価パフォーマンス
138.92 USD (+0.40%)
終値
最終更新: 2026年8月17日
158B USD
時価総額
株価変動の要因
As of Aug 17, 2026, GILD closed up 0.40% at $138.92. No new same-company headline was identified in the current news window.
企業概要
事業概要
Gilead Sciences is a biopharmaceutical company with deep roots in antiviral therapy and growing exposure to oncology and inflammation. Its story has evolved from a legacy antiviral leader into a broader commercial and pipeline platform.
所在地とセクター分類
Headquartered in the United States and listed on NASDAQ, Gilead has a global commercial footprint with major exposure to the U.S. and Europe. It sits in large-cap biopharma with a strong commercial base.
ビジネスモデルの特徴
The company generates revenue through branded therapies, lifecycle management, and pipeline reinvestment across multiple therapeutic areas. Investors focus on HIV, hepatitis, oncology, and the ability to keep replacing mature revenue streams with new assets.
バイオ業界での位置付け
Gilead is a mature large-cap biotech company with enough pipeline depth to retain catalyst sensitivity. It is less binary than development-stage names, but major launch, approval, and partnership updates still matter.
今後のカタリスト
- Gilead’s biggest near-term catalyst is lenacapavir, especially prevention and filing progress, alongside Trodelvy and the oncology franchise. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.
最近のニュース
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。